We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Blood-Brain-Barrier Opening Device Enhances Chemotherapy Drug Delivery to Brain Tissue

By HospiMedica International staff writers
Posted on 08 Feb 2024
Print article
mage: SonoCloud uses the therapeutic potential of pulsed ultrasound to temporarily disrupt the blood-brain barrier (Photo courtesy of Carthera)
mage: SonoCloud uses the therapeutic potential of pulsed ultrasound to temporarily disrupt the blood-brain barrier (Photo courtesy of Carthera)

The blood-brain barrier (BBB) presents a significant challenge in treating gliomas, a type of diffuse tumor that infiltrates the peri-tumoral normal brain. This barrier prevents over 95% of small-molecule drugs and all large-molecule drugs from entering the brain, thus reducing their therapeutic impact. Now, an implantable device utilizes the power of pulsed ultrasound to temporarily open the BBB. This provides a window period during which drug therapies can be administered and can reach the brain in higher and more effective concentrations when the BBB is disrupted.

Carthera’s (Lyon, France) SonoCloud device is designed to be implanted in a skull window beneath the skin, remaining invisible from the outside. When activated for a few minutes via a transdermal needle connected to an external control unit, the device employs low intensity pulsed ultrasound (LIPU) to breach the BBB for several hours. This window of opportunity allows for the administration of drug therapies. The concept of using LIPU to disrupt the BBB has been under pre-clinical development for over two decades. The technology leverages low-intensity ultrasound, akin to levels used in diagnostic imaging, in conjunction with an intravenous microbubble agent to stimulate a therapeutic effect. The LIPU causes the injected microbubbles in brain microvessels to vibrate, mechanically disrupting the BBB’s tight junctions, enhancing active transport across the BBB, and reducing active drug efflux transporters.

Carthera has developed multiple versions of the SonoCloud device, including SonoCloud-1 and SonoCloud-9. These MRI-compatible devices are engineered to disrupt large regions of the BBB, aiming to improve the therapeutic efficacy of drugs in specific brain areas. Currently, these devices are undergoing clinical trials for glioblastoma, brain metastases, and Alzheimer’s Disease. Carthera has initiated the SONOBIRD clinical trial, an open-label, comparative, randomized, multicenter study with a two-arm design and a 1:1 ratio. This trial will assess the overall survival of glioblastoma patients treated with carboplatin chemotherapy in conjunction with the SonoCloud-9 system to breach the BBB. Outcomes will be compared against standard regimens recommended by medical consensus, such as lomustine or temozolomide. Additionally, the trial aims to evaluate the effectiveness of the SonoCloud-9 and carboplatin treatment in delaying or reducing tumor growth.

“The launch of the SONOBIRD trial is a significant achievement in the clinical development of the SonoCloud-9 system. If the efficacy of carboplatin in combination with our device is proven, it will change the paradigm of how we treat glioblastoma,” said Carole Desseaux, chief clinical officer at Carthera

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ultrasound Needle Guide
Ultra-Pro II

Print article

Channels

Critical Care

view channel
Image: The flexible, gas-filled balloon is placed in the main pulmonary artery and connected by a catheter to a hollow reservoir (Photo courtesy of Aria CV)

Implantable Device for Pulmonary Hypertension Reduces Cardiac Workload and Enhances Blood Flow

Pulmonary hypertension is a severe, progressive disease affecting as many as 70 million people globally. It develops when the walls of the pulmonary arteries become rigid, losing their ability to stretch... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.